Quick Answer
Allogene Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Allogene Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $22.0K | -76.8% |
| 2023 | $95.0K | -39.1% |
| 2022 | $156.0K | -99.9% |
| 2021 | $114.09M | — |
| 2020 | $0.00 | — |
| 2019 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | -100.0% | — |
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | -100.0% |
| March 31, 2024 | $22.0K | -26.7% | +0.0% |
| September 30, 2023 | $22.0K | -55.1% | +0.0% |
| June 30, 2023 | $22.0K | -74.4% | -26.7% |
- Allogene Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: